After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, NAMS falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of NewAmsterdam Pharma Company NV is $2.71B. A total of 0.81 million shares were traded on the day, compared to an average of 888.60K shares.
In the most recent transaction, Kooij Louise Frederika sold 8,269 shares of NAMS for 24.86 per share on Aug 25 ’25. After the transaction, the Chief Accounting Officer now owns 15,000 company shares. In a previous transaction on Aug 25 ’25, Kooij Louise Frederika bought 8,269 shares at 25.19 per share.
Among the insiders who sold shares, Kastelein Johannes Jacob Piete disposed of 50,000 shares on Aug 22 ’25 at a per-share price of $25.14. This resulted in the Chief Scientific Officer holding 69,302 shares of NAMS after the transaction. In another insider transaction, Kastelein Johannes Jacob Piete sold 50,000 shares at $24.29 per share on Aug 21 ’25. Company shares held by the Chief Scientific Officer now total 119,302.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, NAMS has a high of $27.29 and a low of $14.06.
As of this writing, NAMS has an earnings estimate of -$0.36 per share for the current quarter. EPS was calculated based on a consensus of 12.0 estimates, with a high estimate of -$0.24 per share and a lower estimate of -$0.44. The company reported an EPS of -$0.16 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. NAMS’s latest balance sheet shows that the firm has $60.11M in Cash & Short Term Investments as of fiscal 2021. There were $185.68k in debt and $11.19M in liabilities at the time. Its Book Value Per Share was $6.92, while its Total Shareholder’s Equity was $56.37M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NAMS is Buy with a score of 4.60.
